STOCK TITAN

Connect Biopharma: Ikarian reports 3.4% passive stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Connect Biopharma Holdings Ltd (CNTB) is the issuer in an amended Schedule 13G in which Ikarian Capital, LLC and Neil Shahrestani report a beneficial ownership position of 2,163,352 ordinary shares, or 3.4% of the class. The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts; Ikarian Capital reports shared voting and dispositive power over 2,163,352 shares. CNTB had 62,974,309 ordinary shares outstanding as of July 31, 2026, the denominator used for the reported 3.4%.

Beneficial ownership position 2,163,352 ordinary shares Reported by Ikarian Capital, LLC and Neil Shahrestani
Class ownership 3.4% Percentage reported using 62,974,309 ordinary shares outstanding as of July 31, 2026
Shared voting and dispositive power 2,163,352 shares each Reported for each reporting person
Ordinary shares outstanding 62,974,309 shares As of July 31, 2026; denominator used for the reported ownership percentage
beneficial ownership regulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 2,163,352.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 2,163,352.00"
separately managed accounts financial
"certain separately managed accounts managed by Ikarian Capital"
A separately managed account is an investment portfolio owned by a single investor but professionally managed to that investor’s specific goals and preferences, rather than pooled with other clients’ money. It matters to investors because it offers greater customization, tax control and transparency—like hiring a personal chef instead of eating from a shared buffet—though it often requires higher minimums and can have different fee and liquidity implications.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CNTB shares did Ikarian Capital and Neil Shahrestani report?

They reported a beneficial ownership position of 2,163,352 CNTB ordinary shares, equal to 3.4% of the class.

Who holds the CNTB shares reported by Ikarian Capital and Neil Shahrestani?

The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts. Ikarian Capital serves as investment manager to the Fund and sub-adviser to the accounts; Neil Shahrestani ultimately controls Ikarian Capital indirectly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





207523101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent ordinary shares, par value $0.000174 per share ("Ordinary Shares") of Connect Biopharma Holdings Limited (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 62,974,309 Ordinary Shares of the Issuer outstanding as of July 31, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on August 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent Ordinary Shares of the Issuer held by the Fund and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 62,974,309 Ordinary Shares of the Issuer outstanding as of July 31, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026.


SCHEDULE 13G



Ikarian Capital, LLC
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:11/16/2026
Neil Shahrestani
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:11/16/2026
Exhibit Information

A Joint Filing Agreement is incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on December 15, 2025 by the Reporting Persons with the SEC.

Keep reading